The research chair honours the contributions of (right) Dr. Joseph Chin and (left) Bob Hardie in cancer research and patient care for over four decades. (Sarah Folkes-Fergusson/LHSF)
The research chair honours the contributions of ( right ) Dr. Joseph Chin and ( left ) Bob Hardie in cancer research and patient care for over four decades. (Sarah Folkes-Fergusson/LHSF) Chin-Hardie Chair in Urologic Oncology bolsters Western's leadership in developing life-saving interventions for cancers of the bladder, kidney and prostate Elevating its legacy of cutting-edge cancer research and patient care, Western has established the Chin-Hardie Chair in Urologic Oncology at the Schulich School of Medicine & Dentistry. The $4-million endowed chair, funded in partnership with Western and London Health Sciences Foundation (LHSF), will focus on driving innovation in research, enhancing patient care and transforming how cancers of the urinary tract and the male reproductive system are diagnosed and treated. The chair is a tribute to the contributions of two remarkable individuals who have had an impact on cancer research and patient care for more than four decades, Dr. Joseph Chin and Bob Hardie. Chin, a leader in urologic oncology and professor emeritus of surgery in the division of urology at Schulich Medicine & Dentistry, is widely respected for his exceptional leadership in innovative medical procedures, including advanced surgery of the prostate using robotic technology and surgery using extreme cold produced by liquid nitrogen or argon gas to destroy cancer cells and abnormal tissue. Hardie, a retired research associate in the same division, has been a valued donor and LHSF partner for more than three decades.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
